DGRO’s December Rebalance Could Reshape Healthcare Exposure: Here’s What to Watch
DGRO's next index rebalance could quietly shift millions of dollars across healthcare and financials, and one overlooked holding sits at the center of the trade. Here is why the December reconstitution deserves more attention than investors are giving it.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) trades near $77, up roughly 11% year to date year-to-date. The fund’s growth-focused screen has favored quality compounders, but investors chasing headline yield have found more juice in higher-yielding peers like SCHD.
DGRO’s mandate is narrow. It tracks the Morningstar US Dividend Growth Index, which requires at least five years of uninterrupted dividend growth, excludes the top 10% of yielders, and screens out any company with a payout ratio above 75%. That yield-trap filter is what separates DGRO from SCHD and explains why the fund tilts toward large-cap compounders across 399 positions, with financials, tech, healthcare, and staples doing most of the work.
The Macro Factor That Matters Most: The 10-Year Treasury Yield
The single biggest swing factor for DGRO over the next 12 months is the 10-year Treasury yield, which sits at 4.62%, just below its 12-month high of 4.67%. On a percentile basis, current yields rank in the 99th percentile of the past year. That is the definition of a headwind for dividend-growth equities.
Coca-Cola, a top-10 holding, yields roughly 2.5%. McDonald’s yields under 3%. Investors buying DGRO for income are collecting less than they would from a risk-free 10-year note, so the fund only makes sense if the dividends grow meaningfully. When Treasuries drift higher, the math gets worse, and MCD’s roughly 11% YTD decline is a live example.
Watch two things: the CME FedWatch tool for rate-cut probabilities, and each 10-year auction (results are on TreasuryDirect the same day). The Fed has held the funds rate at 3.75% for seven months. If the 10-year cracks below 4.25% on softer inflation data, expect DGRO’s staples and healthcare sleeves to catch a bid quickly. If it pushes through 4.75%, the opposite.
The Fund-Specific Signal: The December Rebalance
DGRO’s index rebalances semi-annually in June and December, and the mechanics are worth understanding. The April 30, 2026 holdings snapshot shows something telling: Johnson & Johnson does not appear in the top positions despite being a Dividend King with 64 consecutive years of hikes. Meanwhile, JNJ has quietly surged roughly 66% over the past year. If JNJ’s weighting is reset higher at the December reconstitution, that alone can shift the fund’s yield and growth profile.
The rebalance also polices the 75% payout-ratio cap. Any name whose payout ratio breaches the ceiling gets cut. Check iShares’ holdings page in mid-December: names dropped or added by more than 50 basis points are your signal for how DGRO’s factor exposure has shifted.
What to Watch
The single most important macro signal is the 10-year Treasury yield breaking meaningfully below 4.25% or above 4.75%. The single most important fund signal is the December 2026 index rebalance and whether JNJ’s weight is restored, since that one holding materially changes the healthcare-versus-financials balance of the portfolio for the next six months.
Contact [email protected] for any questions or corrections.
Marc Guberti is a personal finance writer who has written for US News & World Report, Business Insider, Newsweek and other publications. He also hosts the Breakthrough Success Podcast which teaches listeners how to use content marketing to grow their businesses.
